Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | CDK4 | P11802 | 2/20 | 0.39 |
| ▸ | CDK2 | P24941 | 2/20 | 0.39 |
| ▸ | CDK6 | Q00534 | 2/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.36 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.35 |
| ▸ | PDCD1 | Q15116 | 2/20 | 0.34 |
| ▸ | CD274 | Q9NZQ7 | 2/20 | 0.34 |
| ▸ | ATR | Q13535 | 1/20 | 0.34 |
| ▸ | BTK | Q06187 | 1/20 | 0.33 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.33 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.33 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.33 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.32 |
| ▸ | OGA | O60502 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18291451 | 0.85 | PDCD1 (0.48) | MAPTSMN1; SMN2CDK4CDK2CDK6 | |
| SCHEMBL27251619 | 0.84 | EGFR (0.32) | — | |
| SCHEMBL16624105 | 0.82 | ASIC3 (0.39) | MAPTSMN1; SMN2CDK4CDK2CDK6 | |
| SCHEMBL20203493 | 0.82 | MAPT (0.38) | MAPTSMN1; SMN2CDK4CDK2CDK6 | |
| SCHEMBL18806115 | 0.80 | MAPT (0.36) | MAPTSMN1; SMN2CDK4CDK2CDK6 | |
| SCHEMBL16624106 | 0.80 | PDCD1 (0.41) | MAPTSMN1; SMN2CDK4CDK2CDK6 | |
| SCHEMBL11129370 | 0.79 | CDK4 (0.35) | CDK4CDK2CDK6PDE10APDCD1 | |
| SCHEMBL17993870 | 0.78 | CDK4 (0.37) | MAPTSMN1; SMN2CDK4CDK2CDK6 | |
| SCHEMBL21730188 | 0.78 | MAPT (0.36) | MAPTSMN1; SMN2CDK4CDK2CDK6 | |
| SCHEMBL26779767 | 0.78 | SLC6A9 (0.38) | MAPTSMN1; SMN2CDK4CDK2CDK6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160237071-A1 | T-TYPE CALCIUM CHANNEL INHIBITOR | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2016-08-18 | — | — | US | disclosed |
| EP-3053917-A1 | T-TYPE CALCIUM CHANNEL BLOCKER | Nissan Chemical Industries, Ltd. (JP) | 2016-08-10 | — | — | EP | disclosed |
| WO-2015050212-A1 | T-TYPE CALCIUM CHANNEL BLOCKER | 日産化学工業株式会社 | 2015-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160237071-A1 | T-TYPE CALCIUM CHANNEL INHIBITOR | CACNA1I, CACNA1G, CACNA1H | MAPT 479/4885SMN1; SMN2 4489/4885CDK4 2082/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.